PURPOSE: Despite successful primary treatment of nasopharyngeal carcinoma (NPC), the incidence of distant metastasis remains 25-34 %. Treatment options are limited, and survival is poor. Intratumoural Epstein-Barr virus (EBV) was used as treatment target. In NPC, EBV is present in a latent state, expressing only few non-immunogenic viral products. Gemcitabine and valproic acid can trigger EBV to the lytic state, wherein viral kinases are expressed, making EBV-positive tumour cells susceptible for antiviral therapy with, i.e. valganciclovir, and inducing an EBV-specific immune response. METHODS: This drug combination was applied in eight patients with EBV-positive NPC, refractory to conventional treatment. The primary endpoints were safety, tolerability and clinical response. Secondary endpoint was to get proof of concept based on biomarkers, i.e. pharmacokinetics, EBV-DNA load in whole blood and nasopharyngeal brushes, EBV-RNA profiling for proof of lytic induction, EBV-IgG and EBV-IgA levels and diversity and EBV-specific T cell response. RESULTS: The best observed clinical response was partial in two patients (25 %) and stable disease in three patients (37.5 %). The median survival was 9 months (95 % confidence interval 7-17 months). Effective dose levels were reached. Peaking of EBV-DNA loads in blood and brush proved the biological effect on EBV during most treatment cycles. In one patient, RNA profiling confirmed lytic EBV induction. EBV-IgG and EBV-IgA antibody levels were already high before treatment and did not change during treatment. No changes in EBV-specific T cell response were detected. CONCLUSION: The treatment was safe with manageable side effects, clinical response was observed, and viral activation corroborated.
PURPOSE: Despite successful primary treatment of nasopharyngeal carcinoma (NPC), the incidence of distant metastasis remains 25-34 %. Treatment options are limited, and survival is poor. Intratumoural Epstein-Barr virus (EBV) was used as treatment target. In NPC, EBV is present in a latent state, expressing only few non-immunogenic viral products. Gemcitabine and valproic acid can trigger EBV to the lytic state, wherein viral kinases are expressed, making EBV-positive tumour cells susceptible for antiviral therapy with, i.e. valganciclovir, and inducing an EBV-specific immune response. METHODS: This drug combination was applied in eight patients with EBV-positive NPC, refractory to conventional treatment. The primary endpoints were safety, tolerability and clinical response. Secondary endpoint was to get proof of concept based on biomarkers, i.e. pharmacokinetics, EBV-DNA load in whole blood and nasopharyngeal brushes, EBV-RNA profiling for proof of lytic induction, EBV-IgG and EBV-IgA levels and diversity and EBV-specific T cell response. RESULTS: The best observed clinical response was partial in two patients (25 %) and stable disease in three patients (37.5 %). The median survival was 9 months (95 % confidence interval 7-17 months). Effective dose levels were reached. Peaking of EBV-DNA loads in blood and brush proved the biological effect on EBV during most treatment cycles. In one patient, RNA profiling confirmed lytic EBV induction. EBV-IgG and EBV-IgA antibody levels were already high before treatment and did not change during treatment. No changes in EBV-specific T cell response were detected. CONCLUSION: The treatment was safe with manageable side effects, clinical response was observed, and viral activation corroborated.
Authors: S A Veltkamp; M J X Hillebrand; H Rosing; R S Jansen; E R Wickremsinhe; E J Perkins; J H M Schellens; J H Beijnen Journal: J Mass Spectrom Date: 2006-12 Impact factor: 1.982
Authors: Y Bensouda; W Kaikani; N Ahbeddou; R Rahhali; M Jabri; H Mrabti; H Boussen; H Errihani Journal: Eur Ann Otorhinolaryngol Head Neck Dis Date: 2010-12-21 Impact factor: 2.080
Authors: Chrystal U Louis; Karin Straathof; Catherine M Bollard; Sravya Ennamuri; Claudia Gerken; Teresita T Lopez; M Helen Huls; Andrea Sheehan; Meng-Fen Wu; Hao Liu; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk Journal: J Immunother Date: 2010 Nov-Dec Impact factor: 4.456
Authors: Maarten A Wildeman; Renske Fles; Camelia Herdini; Rai S Indrasari; Andrew D Vincent; Maesadji Tjokronagoro; Sharon Stoker; Johan Kurnianda; Baris Karakullukcu; Kartika W Taroeno-Hariadi; Olga Hamming-Vrieze; Jaap M Middeldorp; Bambang Hariwiyanto; Sofia M Haryana; I Bing Tan Journal: PLoS One Date: 2013-05-10 Impact factor: 3.240
Authors: Marlinda Adham; Sharon D Stoker; Maarten A Wildeman; Lisnawati Rachmadi; Soehartati Gondhowiardjo; Djumhana Atmakusumah; Djayadiman Gatot; Renske Fles; Astrid E Greijer; Bambang Hermani; Jaap M Middeldorp; I Bing Tan Journal: PLoS One Date: 2014-07-14 Impact factor: 3.240
Authors: Tanner Dalton; Ekaterina Doubrovina; Dmitry Pankov; Raymond Reynolds; Hanna Scholze; Annamalai Selvakumar; Teresa Vizconde; Bhumesh Savalia; Vadim Dyomin; Christoph Weigel; Christopher C Oakes; Alicia Alonso; Olivier Elemento; Heng Pan; Jude M Phillip; Richard J O'Reilly; Benjamin E Gewurz; Ethel Cesarman; Lisa Giulino-Roth Journal: Blood Date: 2020-05-21 Impact factor: 22.113
Authors: Raul S Gonzalez; Justin M M Cates; Frank Revetta; Loralee A McMahon; Kay Washington Journal: Am J Clin Pathol Date: 2017-11-20 Impact factor: 2.493
Authors: Zlata Novalić; Sandra A W M Verkuijlen; Mariska Verlaan; Jos L H Eersels; Inge de Greeuw; Carla F M Molthoff; Jaap M Middeldorp; Astrid E Greijer Journal: J Med Virol Date: 2017-08-29 Impact factor: 2.327